[September 02, 2014]

Sorin Group Announces First World Implant of CROWN PRT(TM) Heart Valve

Sorin Group (MIL:SRN), (Reuters (News - Alert) Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced today the first world implant of its CROWN PRT bioprosthetic aortic valve. The implant was performed in Austria at the Salzburg University Clinic by Prof. Rainald Seitelberger, M.D., and Christian Dinges, M.D.

"Our first experience with CROWN PRT has been extremely positive," said Professor Seitelberger. "The short two-minute rinse time proved very convenient to streamline intraoperative handling and save on aortic clamp time. The visible commissural markers and the smooth sewing cuff facilitated valve suturing into position. The valve adapted perfectly to the aortic annulus ensuring excellent stability."

"During the implant, CROWN PRT demonstrated very good pressure gradients as measured by transesophageal echocardiography," continued Professor Seitelberger. "A meaningful number of implantations will be required to thoroughly assess the valve's overall performance. However, this first implant is very promising."

CROWN PRT is the latest advancement in stented aortic bioprosthesis technology, featuring surgeon-friendly design, optimal hemoynamics and the patented Phospholipid Reduction Treatment (PRT) to bolster durability through mitigation of calcium uptake¹.

"The CROWN PRT implant performed by Professor Seitelberger and his team represents a key successful step to strategically grow our presence in the tissue heart valve segment worldwide," said Michel Darnaud, President, Cardiac Surgery Business Unit, Sorin Group (News - Alert). "The most rewarding aspect of this implant is to see Sorin's innovative technology deliver on its promise of greater standards both for physicians and patients."

1. Based on 60-day animal model. Sorin Group 2014. Data on file.

About Sorin Group
Sorin Group (www.sorin.com) is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3,500 employees worldwide, Sorin Group focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement prostheses) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose arrhythmias and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.

For more information, please visit www.sorin.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140902005413/en/

[ Back To TMCnet.com's Homepage ]